Antithrombotic therapy for the cardiowest temporary total artificial heart

Texas Heart Institute Journal

Volumn 37, Issue 2, 2010, Pages 149-158

  Ensor, Christopher R ^a   Cahoon, William D ^b   Crouch, Michael A ^c   Katlaps, Gundars J ^b   Hess, Michael L ^b   Cooke, Richard H ^b   Gunnerson, Kyle J ^b   Kasirajan, Vigneshwar ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SOUTHERN UNIVERSITY   (United States)

Author keywords

Anticoagulants administration dosage pharmacokinetics therapeutic use; Antithrombins administration Dosage therapeutic use; Combined modality therapy; Complement activation; Equipment design; Fibrinolytic agents therapeutic use; Heart failure therapy; Heart, artificial adverse effects trends; Heart assist devices adverse effects; Platelet aggregation; Thrombelastography; Thromboembolism etiology prevention control

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; HIRULOG; LEPIRUDIN; PENTOXIFYLLINE; PHENPROCOUMON; WARFARIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTIFICIAL HEART; BLEEDING; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; EQUIPMENT DESIGN; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMPLANTATION; INTRACARDIAC THROMBOSIS; NONHUMAN; PHARMACOGENOMICS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOELASTOGRAPHY; ANIMAL; ARTIFICIAL HEART PACEMAKER; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; DRUG MONITORING; GENETICS; METHODOLOGY; PROSTHESIS; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEART FAILURE; HEART, ARTIFICIAL; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; THROMBOSIS; TREATMENT OUTCOME;

EID: 77954944940     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
2. 2001 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Vol. 1. Department of Health and Human Services, Health Resources & Services Administration, Office of Special Programs, Division of Transplantation; Rock-ville, MD. p. 439-83.
3. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004;351(9): 859-67.
4. Copeland JG, Arabia FA, Tsau PH, Nolan PE, McClellan D, Smith RG, Slepian MJ. Total artificial hearts: bridge to transplantation. Cardiol Clin 2003;21(1):101-13.
5. Schoen FJ, Clagett GP, Hill JD, Chenoweth DE, Anderson JM, Eberhart RC. The biocompatibility of artificial organs. ASAIO Trans 1987;33(4):824-33.
6. Nielsen VG, Kirklin JK, Holman WL, Steenwyk BL, George JF, Zhou F, et al. Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinoly-sis. ASAIO J 2008;54(4):351-8.
7. Kormos RL, Borovetz HS, Griffith BP, Hung TC. Rheo-logic abnormalities in patients with the Jarvik-7 total artificial heart. ASAIO Trans 1987;33(3):413-7.
8. Dintenfass L. Red cell rigidity, Tk, and filtration. Clin Hemorheol 1985;5:241-4.
9. Amir O, Bracey AW, Smart FW, Delgado RM 3rd, Shah N, Kar B. A successful anticoagulation protocol for the first HeartMate II implantation in the United States. Tex Heart Inst J 2005;32(3):399-401.
10. Myers TJ, Robertson K, Pool T, Shah N, Gregoric I, Frazier OH. Continuous flow pumps and total artificial hearts: management issues. Ann Thorac Surg 2003;75(6 Suppl):S79-85.
11. Joist JH, Pennington DG. Platelet reactions with artificial surfaces. ASAIO Trans 1987;33(3):341-4.
12. Guo Z, Bussard KM, Chatterjee K, Miller R, Vogler EA, Siedlecki CA. Mathematical modeling of material-induced blood plasma coagulation. Biomaterials 2006;27(5):796-806.
13. Butchart EG, Li HH, Payne N, Buchan K, Grunkemeier GL. Twenty years' experience with the Medtronic Hall valve. J Thorac Cardiovasc Surg 2001;121(6):1090-100.
14. Fiore AC, Barner HB, Swartz MT, McBride LR, Labovitz AJ, Vaca KJ, et al. Mitral valve replacement: randomized trial of St. Jude and Medtronic Hall prostheses. Ann Thorac Surg 1998;66(3):707-13.
15. Szefner J, Cabrol C. Control and treatment of hemostasis in patients with a total artificial heart: the experience of La Pitié. In: Pifarré R, editor. Anticoagulation, hemostasis, and blood preservation in cardiovascular surgery. Philadelphia: Hanley & Belfus; Mosby (distributor); 1993. p. 237-64.
16. Miller LW, Pagani FD, Russell SD, John R, Boyle AJ, Aar-onson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357(9): 885-96.
17. Crouch MA, Kasirajan V, Cahoon W, Katlaps GJ, Gunnerson KJ. Successful use and dosing of bivalirudin after temporary total artificial heart implantation: a case series. Pharmaco-therapy 2008;28(11):1413-20.
18. Nolan PE, Arabia FA, Smith RG, Sethi GK, Bose RK, Banchy ME, et al. Stroke outcomes following implantation of the Car-dioWest total artificial heart [abstract]. ASAIO J 2002;48(2): 145.
19. Szefner J. Control and treatment of hemostasis in cardiovascular surgery. The experience of La Pitie Hospital with patients on total artificial heart. Int J Artif Organs 1995;18(10):633-48.
20. Glauber M, Szefner J, Senni M, Gamba A, Mamprin F, Fioc-chi R, et al. Reduction of haemorrhagic complications during mechanically assisted circulation with the use of a multi-system anticoagulation protocol. Int J Artif Organs 1995;18(10): 649-55.
21. Copeland JG, Arabia FA, Smith RG, Sethi GK, Nolan PE, Banchy ME. Arizona experience with CardioWest Total Artificial Heart bridge to transplantation. Ann Thorac Surg 1999; 68(2):756-60.
22. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) [published erratum appears in Chest 2008;134(2):473]. Chest 2008;133(6 Suppl):141S-159S.
23. Schenk S, El-Banayosy A, Prohaska W, Arusoglu L, Mor-shuis M, Koester-Eiserfunke W, et al. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. J Thorac Cardiovasc Surg 2006;131(6):1373-81.e4.
24. Warkentin TE, Greinacher A, Koster A, Lincoff AM; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):340S-380S.
25. Stratmann G, deSilva AM, Tseng EE, Hambleton J, Balea M, Romo AJ, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 2004;98(6):1635-9.
26. Angiomax (bivalirudin) for injection [package insert]. The Medicines Company; Parsippany, NJ. 2005 Dec 6 [cited 2010 Mar 8]. Available from: http://www.angiomax.com/Files/ SalesAidRef/PI.pdf.
27. Koster A, Buz S, Krabatsch T, Dehmel F, Hetzer R, Kuppe H, Dyke C. Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system. J Card Surg 2008;23(4):321-3.
28. Nielsen VG, Steenwyk BL, Gurley WQ, Pereira SJ, Lell WA, Kirklin JK. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as hepa-rin-activated antithrombin in vitro. J Heart Lung Transplant 2006;25(6):653-63.
29. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL 2nd, Kirshner R, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131(3):533-9.
30. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006;131(3): 686-92.
31. Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83(2):572-7.
32. Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aron-son S, et al. Off-pump coronary artery bypass with bivaliru-din for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007;84(3):836-9.
33. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):160S-198S.
34. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358 (10):999-1008.
35. Patrono C, Baigent C, Hirsh J, Roth G; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):199S-233S.
36. Pettigrew LC. Antithrombotic drugs for secondary stroke prophylaxis. Pharmacotherapy 2001;21 (4):452-63.
37. Dipyridamole injection USP [package insert]. Bedford Laboratories; Bedford, Oh. 2007 Dec [cited 2010 Mar 8]. Available from: http://www.bedfordlabs.com/BedfordLabsWeb/ products/inserts/DPP06.pdf.
38. Gladding P, Webster M, Ormiston J, Olsen S, White H. Anti-platelet drug nonresponsiveness [published erratum appears in Am Heart J 2008;156(3):563]. Am Heart J 2008;155(4):591-9.
39. Trental (pentoxifylline) tablet, film coated [package insert]. sanofi-aventis U.S. LLC; Bridgewater, NJ. 2006 Sep [cited 2010 Mar 8]. Available from: http://dailymed.nlm.nih.gov/ dailymed/drugInfo.cfm?id= 8411.
40. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):609S-626S.
41. Sobel M, Verhaeghe R; American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):815S-843S.
42. Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prosta-glandin E1 or intravenous pentoxifylline during training. Circulation 1994;90(2):818-22.
43. MacLaren R. Key concepts in the management of difficult hemorrhagic cases. Pharmacotherapy 2007;27(9 Pt 2):93S-102S.
44. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005;27(2):81-90.
45. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992; 69(3):307-13.
46. Salooja N, Perry DJ. Thrombelastography [published erratum appears in Blood Coagul Fibrinolysis 2002;13(1):75]. Blood Coagul Fibrinolysis 2001;12(5):327-37.
47. Spiess BD. Thromboelastography and cardiopulmonary bypass. Semin Thromb Hemost 1995;21 Suppl 4:27-33.
48. Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9(2):168-73.
49. Harnett MJ, Bhavani-Shankar K, Datta S, Tsen LC. In vitro fertilization-induced alterations in coagulation and fibrinoly-sis as measured by thromboelastography. Anesth Analg 2002; 95(4):1063-6.
50. Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120(3):323-36.
51. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27(6): 647-54.
52. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006;97(1):38-43.
53. Linnemann B, Schwonberg J, Mani H, Prochnow S, Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008;6(4):677-83.
54. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on tran-scriptional regulation and warfarin dose. N Engl J Med 2005; 352(22):2285-93.